1
|
De Leersnijder C, Duchateau C, De Braekeleer K, Deconinck E. Relative response factors and multiple regression models in liquid chromatography to quantify low-dosed components using alternative standards-proof of concept: total Δ9-THC content in cannabis flowers using CBD as reference. Anal Bioanal Chem 2022; 414:6507-6520. [PMID: 35788421 DOI: 10.1007/s00216-022-04208-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 06/21/2022] [Accepted: 06/28/2022] [Indexed: 11/29/2022]
Abstract
A classical quantitative analysis in liquid chromatography is performed using either a one-point calibration or a calibration line, prepared using a reference standard of the compound(s) of interest. However, in some cases, adequate reference standards may be very expensive, rare to obtain, or have limited shelf-life properties. Also, in herbal matrices, multiple compounds could be necessary to be quantified, needing a whole series of different (related) reference standards. In these cases, the use of relative response (sometimes called relative correction factors) factors (RRFs) towards reference standards, different of the compound to be quantified, gained attraction. This study performed a comparison of the use of RRFs and linear relative response factor models (LRRFM) for the quantification of targeted low-dosed compounds using an alternative standard, since it is known that classical RRFs often fail in lower concentration ranges. For this purpose, the determination of the total Δ9-tetrahydrocannabinol (Δ9-THC + Δ9-THC-A) content in dried cannabis flowers, using UHPLC-DAD, was used as a case study. A chromatographic method was implemented and validated, and the use of classical calibration lines, classical RRF, and the LRRFM was applied and compared, with special focus on the concentration around 0.2% (w/w) total Δ9-THC, the legal limit (in most European countries) in these products. Results showed that the newly presented and validated LRRFM approach outperformed the classical RRFs, especially in the low-concentration ranges and that concentrations obtained with the LRRFM were in accordance with the interpolation results obtained with a calibration line.
Collapse
Affiliation(s)
- Cedric De Leersnijder
- ULB- Faculty of Pharmacy - RD3 - Pharmacognosy, Bioanalysis and Drug Discovery Unit - Bld Triomphe, Campus Plaine, CP 205/6 - B - 1050, Brussels, Belgium.,Sciensano - Scientific Direction Physical and Chemical Health Risks - Medicines and health products, Rue Juliette Wytsmanstraat, 14 - 1050, Brussels, Belgium
| | - Céline Duchateau
- ULB- Faculty of Pharmacy - RD3 - Pharmacognosy, Bioanalysis and Drug Discovery Unit - Bld Triomphe, Campus Plaine, CP 205/6 - B - 1050, Brussels, Belgium.,Sciensano - Scientific Direction Physical and Chemical Health Risks - Medicines and health products, Rue Juliette Wytsmanstraat, 14 - 1050, Brussels, Belgium
| | - Kris De Braekeleer
- ULB- Faculty of Pharmacy - RD3 - Pharmacognosy, Bioanalysis and Drug Discovery Unit - Bld Triomphe, Campus Plaine, CP 205/6 - B - 1050, Brussels, Belgium
| | - Eric Deconinck
- ULB- Faculty of Pharmacy - RD3 - Pharmacognosy, Bioanalysis and Drug Discovery Unit - Bld Triomphe, Campus Plaine, CP 205/6 - B - 1050, Brussels, Belgium. .,Sciensano - Scientific Direction Physical and Chemical Health Risks - Medicines and health products, Rue Juliette Wytsmanstraat, 14 - 1050, Brussels, Belgium.
| |
Collapse
|
2
|
Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2022; 1200:123275. [DOI: 10.1016/j.jchromb.2022.123275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 04/25/2022] [Accepted: 04/29/2022] [Indexed: 11/17/2022]
|
3
|
Donnette M, Solas C, Giocanti M, Venton G, Farnault L, Berda-Haddad Y, Hau LTT, Costello R, Ouafik L, Lacarelle B, Ciccolini J, Fanciullino R. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1126-1127:121770. [PMID: 31454720 DOI: 10.1016/j.jchromb.2019.121770] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 07/19/2019] [Accepted: 08/18/2019] [Indexed: 01/27/2023]
Abstract
Purine analogs like aracytine (AraC) are a mainstay for treating acute myeloid leukemia (AML). There are marked differences in drug dosing and scheduling depending on the protocols when treating AML patients with AraC. Large inter-patient pharmacokinetics variability has been reported, and genetic polymorphisms affecting cytidine deaminase (CDA), the liver enzyme responsible for the conversion of Ara-C to inactive uracil arabinoside (AraU) could be a culprit for either life-threatening toxicities or poor efficacy related to substantial changes in plasma exposure levels among patients. The quantitative determination of Ara-C in plasma is challenging due the required sensitivity because of the short half-life of this drug (i.e., <10 min) and the metabolic instability in biological matrix upon sampling possibly resulting in erratic values. We developed and validated a liquid chromatography tandem mass spectrometry method (UPLC-MS/MS) for the simultaneous determination of Ara-C and Ara-U metabolite in human plasma. After simple and rapid precipitation, analytes were successfully separated and quantitated over a 1-500 ng/ml range for Ara-C and 250-7500 ng/ml range for AraU. The performance and reliability of this method was tested as part of an investigational study in AML patients treated with low dose cytarabine and confirmed marked differences in drug exposure levels and metabolic ratio, depending on the CDA status of the patients. Overall, this new method meets the requirements of current bioanalytical guidelines and could be used to monitor drug levels in AML patients with respect to their CDA phenotypes.
Collapse
Affiliation(s)
- Melanie Donnette
- SMARTc: Simulation & Modeling: Adaptative Response for Therapeutics in Cancer, CRCM Inserm UMR 1068 CNRS Faculté de Pharmacie de Marseille, 27 boulevard Jean-Moulin, 13385 Marseille, France
| | - Caroline Solas
- SMARTc: Simulation & Modeling: Adaptative Response for Therapeutics in Cancer, CRCM Inserm UMR 1068 CNRS Faculté de Pharmacie de Marseille, 27 boulevard Jean-Moulin, 13385 Marseille, France; Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 rue Saint-Pierre, 13385 Marseille Cedex 5, France
| | - Madeleine Giocanti
- Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 rue Saint-Pierre, 13385 Marseille Cedex 5, France
| | - Geoffroy Venton
- Hematology and Cellular Therapy Department, La Conception University hospital of Marseille, 147 Boulevard Baille, 13005 Marseille, France
| | - Laure Farnault
- Hematology and Cellular Therapy Department, La Conception University hospital of Marseille, 147 Boulevard Baille, 13005 Marseille, France
| | - Yael Berda-Haddad
- Laboratoire de Biologie Medicale, La Conception University Hospital of Marseille, 147 Boulevard Baille, 13005 Marseille, France
| | - Le Thi Thu Hau
- SMARTc: Simulation & Modeling: Adaptative Response for Therapeutics in Cancer, CRCM Inserm UMR 1068 CNRS Faculté de Pharmacie de Marseille, 27 boulevard Jean-Moulin, 13385 Marseille, France
| | - Régis Costello
- Hematology and Cellular Therapy Department, La Conception University hospital of Marseille, 147 Boulevard Baille, 13005 Marseille, France
| | - L'Houcine Ouafik
- Laboratoire de Transfert en Oncologie Biologie, Nord University Hospital of Marseille, Chemin des Bourrely, 13915 Marseille cedex 20, France
| | - Bruno Lacarelle
- Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 rue Saint-Pierre, 13385 Marseille Cedex 5, France
| | - Joseph Ciccolini
- SMARTc: Simulation & Modeling: Adaptative Response for Therapeutics in Cancer, CRCM Inserm UMR 1068 CNRS Faculté de Pharmacie de Marseille, 27 boulevard Jean-Moulin, 13385 Marseille, France; Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 rue Saint-Pierre, 13385 Marseille Cedex 5, France
| | - Raphaëlle Fanciullino
- SMARTc: Simulation & Modeling: Adaptative Response for Therapeutics in Cancer, CRCM Inserm UMR 1068 CNRS Faculté de Pharmacie de Marseille, 27 boulevard Jean-Moulin, 13385 Marseille, France.
| |
Collapse
|
4
|
Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S. Antineoplastic drugs and their analysis: a state of the art review. Analyst 2017; 142:2273-2321. [DOI: 10.1039/c7an00367f] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We provide an overview of the analytical methods available for the quantification of antineoplastic drugs in pharmaceutical formulations, biological and environmental samples.
Collapse
Affiliation(s)
- Nicolas Guichard
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | - Davy Guillarme
- School of Pharmaceutical Sciences
- University of Geneva
- University of Lausanne
- Geneva
- Switzerland
| | - Pascal Bonnabry
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | | |
Collapse
|